Gun-Wook Kang
Director/Miembro de la Junta en KOREA UNITED PHARM INC. .
Cargos activos de Gun-Wook Kang
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| KOREA UNITED PHARM INC. | Director/Miembro de la Junta | - | - |
| Independent Dir/Board Member | - | - | |
| Seoul National University | Corporate Officer/Principal | - | - |
Pelemed Co., Ltd.
 Pelemed Co., Ltd. Pharmaceuticals: GenericHealth Technology Pelemed Co., Ltd. is a South Korean company based in Seoul that specializes in the development of innovative anticancer drugs. Pelemed's technology platform, PeLeSeLect & AHEDD, overcomes mutation-mediated drug resistance and enables precision drug design for kinase-targeted therapies. The company's pipeline includes several drugs in various stages of development for the treatment of different types of cancer. Pelemed has received funding from the IP Voucher Funded by MSS and has a scientific advisory board that includes experts from the ASAN Medical Center Bio Core Facility. The company was founded in 2019, and its CEOs are Yong-Chul Kim and Soo-Yeon Jang. | Director/Miembro de la Junta | - | - |
| Independent Dir/Board Member | - | - |
Historial de carrera de Gun-Wook Kang
Estadísticas
Internacional
| Corea del Sur | 4 |
Operativa
| Director/Board Member | 2 |
| Independent Dir/Board Member | 2 |
| Corporate Officer/Principal | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| KOREA UNITED PHARM INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Pelemed Co., Ltd.
Pelemed Co., Ltd. Pharmaceuticals: GenericHealth Technology Pelemed Co., Ltd. is a South Korean company based in Seoul that specializes in the development of innovative anticancer drugs. Pelemed's technology platform, PeLeSeLect & AHEDD, overcomes mutation-mediated drug resistance and enables precision drug design for kinase-targeted therapies. The company's pipeline includes several drugs in various stages of development for the treatment of different types of cancer. Pelemed has received funding from the IP Voucher Funded by MSS and has a scientific advisory board that includes experts from the ASAN Medical Center Bio Core Facility. The company was founded in 2019, and its CEOs are Yong-Chul Kim and Soo-Yeon Jang. | Health Technology |
- Bolsa de valores
- Insiders
- Gun-Wook Kang
- Experiencia
